- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01374425
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) (MAVERICC)
2016년 6월 30일 업데이트: Genentech, Inc.
MAVERICC (Marker Evaluation for Avastin Research in CRC): A Randomized Phase II Study of Bevacizumab+mFOLFOX6 Vs. Bevacizumab+FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated with bevacizumab plus leucovorin, 5-fluorouracil, and oxaliplatin (mFOLFOX6) or bevacizumab plus leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI).
The study population will consist of participants with first-line mCRC.
연구 개요
상태
완전한
정황
연구 유형
중재적
등록 (실제)
376
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Oslo, 노르웨이, 0407
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205-7199
-
-
California
-
Bellflower, California, 미국, 90706
-
Duarte, California, 미국, 91010
-
Fountain Valley, California, 미국, 92708
-
Fresno, California, 미국, 93720
-
Hayward, California, 미국, 94545
-
Los Angeles, California, 미국, 90033
-
Oakland, California, 미국, 94611
-
Pleasant Hill, California, 미국, 94523
-
Roseville, California, 미국, 95661
-
Sacramento, California, 미국, 95817
-
Sacramento, California, 미국, 95825
-
San Francisco, California, 미국, 94115
-
San Jose, California, 미국, 95119
-
Santa Clara, California, 미국, 95051
-
South San Francisco, California, 미국, 94080
-
Vallejo, California, 미국, 94589
-
Walnut Creek, California, 미국, 94596
-
-
Colorado
-
Denver, Colorado, 미국, 80218
-
-
Connecticut
-
Stamford, Connecticut, 미국, 06902
-
Trumbull, Connecticut, 미국, 06611
-
-
Florida
-
Hollywood, Florida, 미국, 33021
-
Jacksonville, Florida, 미국, 32256
-
Miami, Florida, 미국, 33136
-
Port Saint Lucie, Florida, 미국, 34952
-
-
Idaho
-
Boise, Idaho, 미국, 83712
-
-
Illinois
-
Joliet, Illinois, 미국, 60435
-
Maywood, Illinois, 미국, 60153
-
Peoria, Illinois, 미국, 61615
-
-
Indiana
-
Goshen, Indiana, 미국, 46526
-
Indianapolis, Indiana, 미국, 46237
-
Terre Haute, Indiana, 미국, 47802
-
-
Kansas
-
Fairway, Kansas, 미국, 66205
-
-
Kentucky
-
Elizabethtown, Kentucky, 미국, 42791
-
-
Maine
-
Scarborough, Maine, 미국, 04074
-
-
Massachusetts
-
Burlington, Massachusetts, 미국, 01805
-
-
Montana
-
Billings, Montana, 미국, 59102
-
-
Nebraska
-
Lincoln, Nebraska, 미국, 68506
-
-
New Jersey
-
Cherry Hill, New Jersey, 미국, 08003
-
Manasquan, New Jersey, 미국, 08736
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131-5636
-
Albuquerque, New Mexico, 미국, 87106
-
Albuquerque, New Mexico, 미국, 87110
-
Farmington, New Mexico, 미국, 87401
-
Las Cruces, New Mexico, 미국, 88011
-
Santa Fe, New Mexico, 미국, 87505
-
-
New York
-
Rochester, New York, 미국, 14642
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
-
Greensboro, North Carolina, 미국, 27403
-
High Point, North Carolina, 미국, 27262
-
Washington, North Carolina, 미국, 27889
-
Winston-salem, North Carolina, 미국, 27103
-
-
Ohio
-
Columbus, Ohio, 미국, 43219
-
Toledo, Ohio, 미국, 43623
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73142
-
-
Pennsylvania
-
Dunmore, Pennsylvania, 미국, 18512
-
Media, Pennsylvania, 미국, 19063
-
Philadelphia, Pennsylvania, 미국, 19107
-
Pittsburgh, Pennsylvania, 미국, 15212
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29414
-
-
Texas
-
Corpus Christi, Texas, 미국, 78404
-
Houston, Texas, 미국, 77090
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
-
Wauwatosa, Wisconsin, 미국, 53226
-
-
-
-
-
Aarau, 스위스, 5000
-
Basel, 스위스, 4031
-
Luzern, 스위스, 6004
-
Zürich, 스위스, 8063
-
-
-
-
-
Cork, 아일랜드
-
Dublin, 아일랜드, 24
-
Galway, 아일랜드
-
-
-
-
-
Tallinn, 에스토니아, 13419
-
Tartu, 에스토니아, 51014
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 1Z2
-
-
-
-
-
Coimbra, 포르투갈, 3000-075
-
Lisboa, 포르투갈, 1649-035
-
Porto, 포르투갈, 4200-072
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Histologically or cytologically confirmed colorectal cancer (CRC) with at least one measurable metastatic lesion by RECIST Version 1.1
- Archival tumor tissue sample must be requested and available prior to study entry. If no archival tumor tissue sample is available, a fresh biopsy tissue sample must be obtained but should be discussed first with the medical monitor. A copy of the local pathology report must be submitted along with the specimens.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Participants with treated brain metastases are eligible for study participation. Participants may not receive ongoing treatment with steroids at Screening. Anticonvulsants (at stable dose) are allowed. Treatment for brain metastases may be whole-brain radiotherapy, radiosurgery, neurosurgery, or a combination as deemed appropriate by the treating physician. Radiotherapy and stereotactic radiosurgery must be completed at least 28 days prior to randomization.
- Female participants should not be pregnant or breastfeeding. Female participants with childbearing potential should agree to use effective, non-hormonal means of contraception during the study and for a period of at least 6 months following the last administration of study drugs. Female participants with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 7 days prior to randomization into the study.
- Male participants must agree to use effective contraception during the study and for a period of at least 6 months following the last administration of study drugs, even if they have been surgically sterilized.
Exclusion Criteria:
- Any prior systemic treatment for mCRC
- Adjuvant chemotherapy for CRC completed <12 months
- Evidence of Gilbert's syndrome or of homozygosity for the UGT1A1*28 allele
- Known positivity for human immunodeficiency virus (HIV)
- Malignancies other than mCRC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent
- Radiotherapy to any site for any reason within 28 days prior to randomization, except for palliative radiotherapy to bone lesions within 14 days prior to randomization
- Clinically detectable third-space fluid collections that cannot be controlled by drainage or other procedures prior to study entry
- Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Bevacizumab + mFOLFOX6
Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity.
Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
|
5-Fluorouracil 400 milligrams per meter-squared (mg/m^2) by IV bolus and subsequent 2400 mg/m^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity.
If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
다른 이름들:
Leucovorin 400 mg/m^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Oxaliplatin 85 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Capecitabine 850 or 1000 mg/m^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
|
실험적: Bevacizumab + FOLFIRI
Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity.
Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
|
5-Fluorouracil 400 milligrams per meter-squared (mg/m^2) by IV bolus and subsequent 2400 mg/m^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity.
If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
다른 이름들:
Leucovorin 400 mg/m^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Capecitabine 850 or 1000 mg/m^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
Irinotecan 180 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as greater than or equal to (≥) 20 percent (%) increase in sum of largest diameters (LD) of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 millimeters (mm).
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and High VEGF-A Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and Low VEGF-A Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and High VEGF-A Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and Low VEGF-A Levels
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Overall Survival (OS)
기간: From Baseline until death (maximum up to 45 months overall)
|
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
OS was defined as the time from randomization to death.
The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death (maximum up to 45 months overall)
|
OS in Participants With High ERCC-1 Levels
기간: From Baseline until death (maximum up to 45 months overall)
|
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
OS was defined as the time from randomization to death.
The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death (maximum up to 45 months overall)
|
OS in Participants With Low ERCC-1 Levels
기간: From Baseline until death (maximum up to 45 months overall)
|
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
OS was defined as the time from randomization to death.
The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death (maximum up to 45 months overall)
|
OS in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
기간: From Baseline until death (maximum up to 45 months overall)
|
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
OS was defined as the time from randomization to death.
The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death (maximum up to 45 months overall)
|
Percentage of Participants With Objective Response According to RECIST Version 1.1
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Objective response was defined as complete response (CR) or partial response (PR) according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to less than (<) 10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
The percentage of participants with CR or PR was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Objective response was defined as CR or PR according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
The percentage of participants with CR or PR was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Objective response was defined as CR or PR according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
The percentage of participants with CR or PR was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Objective response was defined as CR or PR according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
The percentage of participants with CR or PR was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Disease Control According to RECIST Version 1.1
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Disease control was defined as CR, PR, or stable disease (SD) according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study.
The percentage of participants with CR, PR, or SD was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Disease control was defined as CR, PR, or SD according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study.
The percentage of participants with CR, PR, or SD was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Disease control was defined as CR, PR, or SD according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study.
The percentage of participants with CR, PR, or SD was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Disease control was defined as CR, PR, or SD according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study.
The percentage of participants with CR, PR, or SD was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Liver Metastasis Resection
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins.
In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1.
R2 was defined as macroscopic positive margins or incomplete resection at time of surgery.
The percentage of participants with resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Complete Liver Metastasis Resection
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins.
In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1.
R2 was defined as macroscopic positive margins or incomplete resection at time of surgery.
The percentage of participants with resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Liver Metastasis Resection in Participants With Low ERCC-1 Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins.
In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1.
R2 was defined as macroscopic positive margins or incomplete resection at time of surgery.
The percentage of participants with resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Complete Liver Metastasis Resection in Participants With Low ERCC-1 Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins.
In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1.
R2 was defined as macroscopic positive margins or incomplete resection at time of surgery.
The percentage of participants with resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
PFS According to RECIST Version 1.1 in Participants With Wild-Type V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Versus Participants With Mutant KRAS
기간: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Tumor assessments were performed according to RECIST Version 1.1.
Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm.
Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy.
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
PFS was defined as the time from randomization to death or disease progression, whichever occurred first.
The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
OS in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
기간: From Baseline until death (maximum up to 45 months overall)
|
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
OS was defined as the time from randomization to death.
The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death (maximum up to 45 months overall)
|
OS in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS
기간: From Baseline until death (maximum up to 45 months overall)
|
Death on study included death from any cause occurring no later than 3 months after the last component of study treatment.
OS was defined as the time from randomization to death.
The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months.
The 95% CI was computed using the method of Brookmeyer and Crowley.
|
From Baseline until death (maximum up to 45 months overall)
|
Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Objective response was defined as CR or PR according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
The percentage of participants with CR or PR was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Objective response was defined as CR or PR according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
The percentage of participants with CR or PR was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
기간: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Disease control was defined as CR, PR, or SD according to RECIST Version 1.1.
CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes.
PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline.
Confirmation of response at a consecutive assessment was not required.
SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study.
The percentage of participants with CR, PR, or SD was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)
|
Percentage of Participants With Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins.
In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1.
R2 was defined as macroscopic positive margins or incomplete resection at time of surgery.
The percentage of participants with resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
기간: At time of resective surgery during study (maximum up to 45 months overall)
|
The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator.
Resection was classified as R0, R1, or R2 following surgery.
R0 was defined as complete resection with clear margins ≥1 mm.
The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported.
The 95% CI was computed using normal approximation to the binomial distribution.
|
At time of resective surgery during study (maximum up to 45 months overall)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
수사관
- 연구 책임자: Christiane Langer, M.D., Genentech, Inc.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2011년 8월 1일
기본 완료 (실제)
2015년 5월 1일
연구 완료 (실제)
2015년 7월 1일
연구 등록 날짜
최초 제출
2011년 6월 14일
QC 기준을 충족하는 최초 제출
2011년 6월 15일
처음 게시됨 (추정)
2011년 6월 16일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2016년 8월 11일
QC 기준을 충족하는 마지막 업데이트 제출
2016년 6월 30일
마지막으로 확인됨
2016년 6월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ML25710
- 2011-004755-39 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
대장암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
5-Fluorouracil에 대한 임상 시험
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedThe Hong Kong Anti-Cancer Society; hong Kong Cancer Fund완전한
-
ClinAssessSanofi; Merck Sharp & Dohme LLC완전한
-
Encube Ethicals Pvt. Ltd.CBCC Global Research완전한
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation Medicine모병II기 결장암 | 3기 결장암 | HER2 양성 대장암 | RAS 야생형 결장암이탈리아
-
National Institute of Public Health, CambodiaEmory University; World Vision International; World Vision, Hong Kong; World Vision, Cambodia완전한
-
Taipei Medical University Shuang Ho Hospital완전한